Forsta AP Fonden Buys 5,300 Shares of Axon Enterprise, Inc $AXON

Forsta AP Fonden lifted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 35.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,300 shares of the biotechnology company’s stock after acquiring an additional 5,300 shares during the quarter. Forsta AP Fonden’s holdings in Axon Enterprise were worth $16,807,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. TCTC Holdings LLC increased its holdings in Axon Enterprise by 75.0% during the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 24 shares during the period. Banque Transatlantique SA bought a new position in shares of Axon Enterprise during the 1st quarter worth $31,000. Flaharty Asset Management LLC purchased a new position in shares of Axon Enterprise during the first quarter valued at $33,000. Hemington Wealth Management increased its stake in shares of Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares during the period. Finally, Whipplewood Advisors LLC raised its holdings in shares of Axon Enterprise by 192.9% in the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 27 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AXON has been the topic of several recent research reports. Barclays dropped their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Bank of America increased their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Cowen reissued a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. The Goldman Sachs Group lowered their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Northland Securities set a $800.00 price target on Axon Enterprise in a report on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $810.71.

Axon Enterprise Stock Performance

Shares of AXON opened at $569.51 on Thursday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The firm has a market cap of $44.94 billion, a PE ratio of 140.62, a P/E/G ratio of 29.49 and a beta of 1.45. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The stock has a fifty day moving average price of $709.82 and a 200-day moving average price of $735.72.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same quarter last year, the firm earned $1.45 earnings per share. The firm’s quarterly revenue was up 30.6% compared to the same quarter last year. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, CAO Jennifer H. Mak sold 77 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the sale, the chief accounting officer owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. The trade was a 0.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeri Williams sold 100 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the sale, the director directly owned 1,416 shares in the company, valued at approximately $1,065,596.64. This represents a 6.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 52,041 shares of company stock worth $36,794,077 over the last ninety days. Company insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.